Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

BUY
$8.86 - $25.04 $114,293 - $323,016
12,900 Added 105.74%
25,100 $258,000
Q2 2022

Aug 03, 2022

BUY
$36.28 - $75.29 $50,792 - $105,406
1,400 Added 12.96%
12,200 $627,000
Q1 2022

May 11, 2022

SELL
$69.73 - $142.9 $104,595 - $214,350
-1,500 Reduced 12.2%
10,800 $795,000
Q4 2021

Feb 08, 2022

SELL
$134.56 - $217.97 $67,280 - $108,985
-500 Reduced 3.91%
12,300 $1.76 Million
Q3 2021

Nov 10, 2021

BUY
$177.8 - $270.58 $106,680 - $162,348
600 Added 4.92%
12,800 $2.65 Million
Q2 2021

Aug 03, 2021

BUY
$121.0 - $257.67 $108,900 - $231,903
900 Added 7.96%
12,200 $2.59 Million
Q4 2020

Feb 11, 2021

BUY
$78.74 - $139.5 $889,762 - $1.58 Million
11,300 New
11,300 $1.26 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $731M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.